{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:37:09Z","timestamp":1792643829384,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["847949"],"award-info":[{"award-number":["847949"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jhepr.2022.100667","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T01:40:29Z","timestamp":1672710029000},"page":"100667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Management of splanchnic vein thrombosis"],"prefix":"10.1016","volume":"5","author":[{"given":"Laure","family":"Elkrief","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Payanc\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5656-1622","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Plessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"d\u2019Alteroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-3939","authenticated-orcid":false,"given":"Maxime","family":"Ronot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-1859","authenticated-orcid":false,"given":"Pierre-Emmanuel","family":"Rautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2022.100667_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jhep.2017.11.004","article-title":"Access to care in rare liver diseases: new challenges and new opportunities","volume":"68","author":"Jones","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jhep.2022.05.033","article-title":"Porto-sinusoidal vascular disorder","volume":"77","author":"De Gottardi","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hep.510310307","article-title":"Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors","volume":"31","author":"Denninger","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","article-title":"Etiology, management, and outcome of the Budd-Chiari syndrome","volume":"151","author":"Darwish Murad","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2022.100667_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.23259","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study","volume":"67","author":"Poisson","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2015.08.024","article-title":"Central obesity is associated with non-cirrhotic portal vein thrombosis","volume":"64","author":"Bureau","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib8","first-page":"847A","article-title":"Impact of cytoreductive therapy on the outcome of patients with myeloproliferative neoplasms and hepato-splanchnic vein thrombosis","volume":"58","author":"Chagneau-Derrode","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13023-014-0153-1","article-title":"Behcet\u2019s disease in Budd-Chiari syndrome","volume":"9","author":"Desbois","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhepr.2022.100667_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2020.06.045","article-title":"Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis","volume":"74","author":"Magaz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26474","article-title":"Paroxysmal nocturnal hemoglobinuria and vascular liver disease: eculizumab therapy decreases mortality and thrombotic complications","author":"Plessier","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jhepr.2022.100667_bib12","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2022.100667_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2014.08.032","article-title":"Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis","volume":"62","author":"Turon","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib14","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2014.120857","article-title":"Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis","author":"Plompen","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jhepr.2022.100667_bib15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/apt.13815","article-title":"Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China","volume":"44","author":"Qi","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100667_bib16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jgh.14925","article-title":"Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: a hospital-based observational study","volume":"35","author":"Fan","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib17","first-page":"3708","article-title":"Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood\u00a0Adv"},{"key":"10.1016\/j.jhepr.2022.100667_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2020.07.043","article-title":"Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis","volume":"74","author":"Kiladjian","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis","volume":"129","author":"Chait","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhepr.2022.100667_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2022.100667_bib21","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1097\/MD.0000000000000496","article-title":"Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis","volume":"94","author":"Qi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhepr.2022.100667_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clinre.2019.10.006","article-title":"Characteristics and outcome of primary Budd-Chiari syndrome due to Beh\u00e7et\u2019s syndrome","volume":"44","author":"Sakr","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2009.06.019","article-title":"Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study","volume":"51","author":"Hoekstra","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4254\/wjh.v7.i6.903","article-title":"Aetiological factors of Budd-Chiari syndrome in Algeria","volume":"7","author":"Afredj","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2021.09.011","article-title":"Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease","volume":"76","author":"De Broucker","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.dld.2021.05.021","article-title":"Acute splanchnic vein thrombosis in patients with COVID-19: a systematic review","volume":"53","author":"Buso","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100667_bib27","doi-asserted-by":"crossref","first-page":"n1931","DOI":"10.1136\/bmj.n1931","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2022.100667_bib28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2021.12.032","article-title":"Impact of SARS-CoV-2 pandemic on vascular liver diseases","volume":"20","author":"Baiges","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib29","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.cgh.2014.04.026","article-title":"Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis","volume":"12","author":"Qi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gut.46.4.534","article-title":"Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon?","volume":"46","author":"Fisher","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100667_bib31","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/liv.14342","article-title":"Congenital antithrombin deficiency in patients with splanchnic vein thrombosis","volume":"40","author":"Baiges","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100667_bib32","doi-asserted-by":"crossref","first-page":"E480","DOI":"10.1111\/hepr.12348","article-title":"Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis of observational studies","volume":"44","author":"Qi","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2022.100667_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jceh.2014.12.007","article-title":"Pregnancy and vascular liver disease","volume":"5","author":"Bissonnette","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib34","first-page":"2364","article-title":"Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study","volume":"96","author":"Janssen","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2022.100667_bib35","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1365-2036.2010.04454.x","article-title":"The epidemiology and clinical features of portal vein thrombosis: a multicentre study","volume":"32","author":"Rajani","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100667_bib36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clinre.2020.03.010","article-title":"Risk factors for vascular liver diseases: vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver","volume":"44","author":"Soret","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib37","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/ajg.2012.231","article-title":"Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia","volume":"107","author":"Rebours","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib38","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s00261-017-1447-2","article-title":"Diagnosis of Budd-Chiari syndrome","volume":"43","author":"Van Wettere","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.jhepr.2022.100667_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12072-017-9810-5","article-title":"Budd-Chiari syndrome\/hepatic venous outflow tract obstruction","volume":"12","author":"Valla","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2022.100667_bib40","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.dld.2018.04.004","article-title":"The epidemiology of Budd-Chiari syndrome in France","volume":"50","author":"Ollivier-Hourmand","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100667_bib41","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/hep.21354","article-title":"Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome","volume":"44","author":"Plessier","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib43","article-title":"Baveno VII - renewing consensus in portal hypertension","author":"de Franchis","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib44","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/gut.2005.071423","article-title":"Favourable medium term outcome following hepatic vein recanalisation and\/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome","volume":"55","author":"Eapen","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100667_bib45","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/hep.26306","article-title":"Good long-term outcome of Budd-Chiari syndrome with a step-wise management","volume":"57","author":"Seijo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib46","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.12668","article-title":"Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome","volume":"39","author":"Tripathi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100667_bib47","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ajg.2009.63","article-title":"Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management","volume":"104","author":"Rautou","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib48","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1053\/j.gastro.2008.05.051","article-title":"TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients","volume":"135","author":"Garcia-Pag\u00e1n","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2022.100667_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"Vascular diseases of the liver","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.510300125","article-title":"Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting","volume":"30","author":"Zeitoun","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib51","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.4081\/hr.2015.5927","article-title":"Long standing eculizumab treatment without anticoagulant therapy in high-risk thrombogenic paroxysmal nocturnal hemoglobinuria","volume":"7","author":"Al-Jafar","year":"2015","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jhepr.2022.100667_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000280466","article-title":"Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis","volume":"123","author":"Randi","year":"2010","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jhepr.2022.100667_bib53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/MEG.0000000000000632","article-title":"Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis","volume":"28","author":"Zaman","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib54","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and cirrhosis","author":"De Gottardi","year":"2016","journal-title":"Liver Int"},{"issue":"22","key":"10.1016\/j.jhepr.2022.100667_bib55","first-page":"449","article-title":"Outcome of Budd-Chiari syndrome (BCS) patients treated with direct oral anticoagulants (DOACs) - an Austrian multicenter study","volume":"S1542\u20133565","author":"Semmler","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib56","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/jgh.14843","article-title":"Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention","volume":"35","author":"Sharma","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102711","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"20","author":"Dufrost","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhepr.2022.100667_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jhep.2010.06.019","article-title":"Bleeding in patients with Budd\u2013Chiari syndrome","volume":"54","author":"Rautou","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib59","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12072-018-9900-z","article-title":"Budd\u2013Chiari syndrome: a focussed and collaborative approach","volume":"12","author":"Mukund","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2022.100667_bib60","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S2468-1253(19)30177-3","article-title":"Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial","volume":"4","author":"Wang","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1148\/radiol.2016152641","article-title":"Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary Budd-Chiari syndrome","volume":"283","author":"Hayek","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2022.100667_bib62","first-page":"155","article-title":"Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome?","volume":"65","author":"Langlet","year":"2002","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.jhepr.2022.100667_bib63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2006.08.016","article-title":"Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome","volume":"46","author":"Bachet","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib64","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/lt.21220","article-title":"Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis","volume":"13","author":"Segev","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhepr.2022.100667_bib65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2009.02.028","article-title":"Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes","volume":"51","author":"Rautou","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib66","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4254\/wjh.v9.i21.945","article-title":"Outcomes of pregnancy in patients with known Budd-Chiari syndrome","volume":"9","author":"Khan","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib67","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/liv.13552","article-title":"Pregnancy outcomes in women with Budd Chiari Syndrome before onset of symptoms and after treatment","volume":"38","author":"Shukla","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100667_bib68","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jhepr.2022.100667_bib69","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/gut.2007.139477","article-title":"Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors","volume":"57","author":"Moucari","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100667_bib70","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1148\/radiol.09090738","article-title":"Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE","volume":"254","author":"Gwon","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2022.100667_bib71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00428-018-2373-6","article-title":"Hepatocellular nodules in vascular liver diseases","volume":"473","author":"Sempoux","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jhepr.2022.100667_bib72","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1007\/s00261-018-1502-7","article-title":"Benign and malignant hepatocellular lesions in patients with vascular liver diseases","volume":"43","author":"Vilgrain","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.jhepr.2022.100667_bib73","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2019.01.009","article-title":"Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome","volume":"70","author":"Van Wettere","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib74","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/apt.13173","article-title":"Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction","volume":"41","author":"Paul","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100667_bib75","article-title":"Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome","volume":"2","author":"Van Wettere","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2022.100667_bib76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/ajg.2017.38","article-title":"Predictive factors of intestinal necrosis in acute mesenteric ischemia: prospective study from an intestinal stroke center","volume":"112","author":"Nuzzo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrgastro.2013.258","article-title":"Imaging in clinical decision-making for portal vein thrombosis","volume":"11","author":"Berzigotti","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib78","article-title":"Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis","author":"Elkrief","year":"2013","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jhepr.2022.100667_bib79","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/hep.28466","article-title":"Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis","volume":"63","author":"Noronha Ferreira","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib80","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2214\/ajr.165.5.7572494","article-title":"Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography","volume":"165","author":"De Gaetano","year":"1995","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhepr.2022.100667_bib81","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1148\/radiol.12111046","article-title":"Liver and spleen stiffness in patients with extrahepatic portal vein obstruction","volume":"263","author":"Sharma","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2022.100667_bib82","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bjs.6319","article-title":"Epidemiology, risk and prognostic factors in mesenteric venous thrombosis","volume":"95","author":"Acosta","year":"2008","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhepr.2022.100667_bib83","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41395-018-0389-9","article-title":"Oral antibiotics reduce intestinal necrosis in acute mesenteric ischemia: a prospective cohort study","volume":"114","author":"Nuzzo","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib84","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/jhep.2000.16597","article-title":"Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy","volume":"32","author":"Condat","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib85","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cgh.2008.07.031","article-title":"Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation","volume":"6","author":"Turnes","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib86","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/j.1572-0241.2007.01477.x","article-title":"Prognostic factors in noncirrhotic patients with splanchnic vein thromboses","volume":"102","author":"Amitrano","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib87","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis","author":"Valeriani","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jhepr.2022.100667_bib88","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200104","article-title":"Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis","volume":"1","author":"Plessier","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2022.100667_bib89","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MEG.0000000000001061","article-title":"Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation","volume":"30","author":"Guillaume","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib90","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jhep.2019.02.015","article-title":"Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis","volume":"71","author":"Hern\u00e1ndez-Gea","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib91","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/apt.15479","article-title":"A\u00a0stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia","volume":"50","author":"Benmassaoud","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100667_bib92","article-title":"Percutaneous portal vein recanalization using self-expandable nitinol stents in patients with non-cirrhotic non-tumoral portal vein occlusion","author":"Marot","year":"2018","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.jhepr.2022.100667_bib93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.dld.2010.06.001","article-title":"Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma","volume":"43","author":"Fanelli","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2022.100667_bib94","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/hep.31915","article-title":"TIPS for adults without cirrhosis with chronic mesenteric venous thrombosis and EHPVO refractory to standard-of-care therapy","volume":"74","author":"Knight","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib95","article-title":"Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction","volume":"4","author":"Artru","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2022.100667_bib96","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1447-0756.2010.01407.x","article-title":"Extra hepatic portal vein obstruction and pregnancy outcome: largest reported experience","volume":"37","author":"Aggarwal","year":"2011","journal-title":"J\u00a0Obstet Gynaecol Res"},{"key":"10.1016\/j.jhepr.2022.100667_bib97","first-page":"676","article-title":"Is pregnancy safe with extrahepatic portal vein obstruction? An analysis","volume":"53","author":"Mandal","year":"2012","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jhepr.2022.100667_bib98","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2012.07.034","article-title":"Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome","volume":"57","author":"Hoekstra","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib99","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jceh.2014.02.003","article-title":"Portal cavernoma cholangiopathy: consensus statement of a working\u00a0party of the Indian national association for study of the liver","volume":"4","author":"Dhiman","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib100","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1136\/gut.2006.103606","article-title":"Portal hypertensive biliopathy","volume":"56","author":"Dhiman","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100667_bib101","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jceh.2013.05.015","article-title":"Pathogenesis of portal cavernoma cholangiopathy: is it compression by collaterals or ischemic injury to bile ducts during portal vein thrombosis?","volume":"4","author":"Puri","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib102","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1053\/jhep.2003.50232","article-title":"Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study","volume":"37","author":"Condat","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib103","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0016-5107(99)70011-8","article-title":"Cholangiopathy associated with portal hypertension: diagnostic evaluation and clinical implications","volume":"49","author":"Malkan","year":"1999","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jhepr.2022.100667_bib104","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/gut.2010.230201","article-title":"Portal cholangiopathy: radiological classification and natural history","volume":"60","author":"Llop","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100667_bib105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","article-title":"Current knowledge and management of portal vein thrombosis in cirrhosis","volume":"75","author":"Senzolo","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib106","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2011.12.034","article-title":"Portal vein thrombosis, cirrhosis, and liver transplantation","volume":"57","author":"Francoz","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib108","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","article-title":"Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors","volume":"75","author":"Turon","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib109","first-page":"E2822","article-title":"Portal thrombosis in cirrhosis: role of thrombophilic disorders","volume":"9","author":"Fortea","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2022.100667_bib110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1471-230X-12-114","article-title":"Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients","volume":"12","author":"Ayala","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MEG.0000000000000325","article-title":"De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system","volume":"27","author":"Abdel-Razik","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib112","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00042737-200507000-00009","article-title":"Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors","volume":"17","author":"Mangia","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib113","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib114","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/apt.15137","article-title":"Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study","volume":"49","author":"Nery","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100667_bib115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s12072-019-09951-6","article-title":"Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2022.100667_bib116","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/liv.15183","article-title":"Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications","volume":"42","author":"Zanetto","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2022.100667_bib117","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/lt.25345","article-title":"Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria","volume":"25","author":"Sherman","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2022.100667_bib118","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2214\/ajr.161.2.8392785","article-title":"Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma","volume":"161","author":"Dodd","year":"1993","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jhepr.2022.100667_bib119","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2022.100667_bib120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12916-018-1069-8","article-title":"Transient portal vein thrombosis in liver cirrhosis","volume":"16","author":"Qi","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.jhepr.2022.100667_bib121","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","article-title":"Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation","volume":"54","author":"Francoz","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2022.100667_bib122","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2004.01.001","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib123","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ajg.2012.452","article-title":"De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes","volume":"108","author":"Maruyama","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib124","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1148\/radiol.12112236","article-title":"Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis","volume":"265","author":"Luca","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2022.100667_bib125","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.cgh.2020.02.037","article-title":"Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation","volume":"18","author":"Zhang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib126","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/lt.22105","article-title":"Portal vein thrombosis and liver transplant survival benefit","volume":"16","author":"Englesbe","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2022.100667_bib127","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/SLA.0000000000000252","article-title":"When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases","volume":"259","author":"Hibi","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2022.100667_bib128","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.32169","article-title":"Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus","volume":"75","author":"Driever","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2022.100667_bib129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","article-title":"A\u00a0prediction model for successful anticoagulation in cirrhotic portal vein thrombosis","volume":"31","author":"Rodriguez-Castro","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"SUPPLEMENT 2","key":"10.1016\/j.jhepr.2022.100667_bib131","first-page":"S191","article-title":"OS-1544 Anticoagulation improves overall survival through portal vein recanalization in patients with cirrhosis and portal vein thrombosis: individual patient data meta-analysis (IMPORTAL study)","volume":"75","author":"Guerrero","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib132","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib133","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2021.09.004","article-title":"AGA technical review on coagulation in cirrhosis","volume":"161","author":"Intagliata","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2022.100667_bib134","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.cgh.2017.10.016","article-title":"Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis","volume":"16","author":"La Mura","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib135","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjmed.2021.05.013","article-title":"Comparison of fondaparinux and low-molecular-weight heparin in the treatment of portal vein thrombosis in cirrhosis","volume":"134","author":"Senzolo","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.jhepr.2022.100667_bib136","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhepr.2019.02.006","article-title":"Anticoagulation in the cirrhotic patient","volume":"1","author":"Turco","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2022.100667_bib137","article-title":"Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis","author":"Mort","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib138","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/liv.14992","article-title":"Safety of direct oral anticoagulants in patients with advanced liver disease","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int"},{"issue":"21","key":"10.1016\/j.jhepr.2022.100667_bib139","first-page":"02033","article-title":"Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"S0168\u20138278","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib140","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2022.100667_bib141","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2022.100667_bib142","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jhepr.2022.100667_bib143","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/MEG.0b013e328338d995","article-title":"Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis","volume":"22","author":"Perarnau","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2022.100667_bib144","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.3748\/wjg.v21.i22.6769","article-title":"Portal vein thrombosis in cirrhosis: controversies and latest developments","volume":"21","author":"Harding","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2022.100667_bib145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/apt.15044","article-title":"Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis","volume":"49","author":"Rodrigues","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2022.100667_bib146","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jvir.2017.08.005","article-title":"Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort","volume":"28","author":"Thornburg","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jhepr.2022.100667_bib147","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1148\/radiol.2015150369","article-title":"Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial","volume":"279","author":"Wang","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jhepr.2022.100667_bib148","article-title":"Renoportal anastomosis during liver transplantation in patients with portal vein thrombosis: first long-term results from a multicenter study","author":"Azoulay","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhepr.2022.100667_bib149","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"EP Europace"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922002397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555922002397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:31:18Z","timestamp":1762900278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555922002397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2589555922002397"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100667","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of splanchnic vein thrombosis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2022.100667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100667"}}